08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

Phrixus preclinical data

In a mouse model of muscular dystrophy, once-daily subcutaneous 1 mg/kg P-188 NF for 8 weeks significantly slowed the decline in 9 of 12 respiratory parameters vs. saline-treated controls. The 9 parameters were respiration rate,...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

Carmeseal-MD regulatory update

Phrixus and Ethicor Pharma Ltd. (London, U.K.) will begin a European access program this month to provide Carmeseal-MD to treat respiratory and cardiac deficits in patients with Duchenne muscular dystrophy (DMD) through specialty physicians. Ethicor...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Phrixus preclinical data

In a mouse model of DMD, subcutaneous Carmeseal improved tidal volume, a measure of respiratory performance, at doses as low as 3 mg/kg given once daily. The study evaluated daily to weekly dosing of 3-300...
07:00 , Jun 25, 2012 |  BioCentury  |  Emerging Company Profile

LoneStar Heart: Straight to the heart

Therapies for heart failure are palliative and aimed primarily at delaying pathological cardiac remodeling and progression to advanced disease. LoneStar Heart Inc. is developing a trio of technologies that it believes have the potential to...
07:00 , Apr 8, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Muscular dystrophy; heart failure Not applicable A study in canines suggests that the membrane sealant poloxamer 188 could help treat muscular dystrophy-associated heart failure. In...
07:00 , Jun 29, 2009 |  BioCentury  |  Emerging Company Profile

Corporate Profile

Phrixus Pharmaceuticals Inc. Ann Arbor, Mich. Technology: Carmeseal poloxamer 188 Disease focus: Heart failure Clinical status: Phase I Founded: 2006 by Thomas Collet, Bruce Markham and Lorraine Reeve University collaborators: University of Michigan , University...
07:00 , Jun 29, 2009 |  BioCentury  |  Emerging Company Profile

Phrixus: Healing Broken Hearts

Several companies have attempted to develop poloxamer 188 for a range of indications, but the compound never made it past Phase III trials. Phrixus Pharmaceuticals Inc. has found new indications for the non-ionic block copolymer...